CancerIQ is a SaaS-based digital health platform that helps providers use genetic information to predict, pre-empt, and prevent disease - starting with cancer.
CancerIQ’s technology enables hospitals to identify, evaluate and manage entire patient populations based on individual genetic risk factors.
CancerIQ was founded in 2013 by Feyi Olopade Ayodele, Haibo Lu and Olufunmilayo (Funmi) Olopade. The company is headquartered in Chicago, Illinois, with an office in San Francisco, California.
CancerIQ, integrated directly into real-time EHR workflows, makes it easy to gather comprehensive patient data, automatically map it to the latest evidence-based guidelines, and expand access to personalized care plans, cutting-edge clinical solutions, and genomic innovations.
CancerIQ is embedded directly into EMR workflows so clinicians in any care setting have the latest genomics research, clinical guidelines, and life sciences innovations at their fingertips.
CancerIQ’s precision health platform is being used by clinicians at more than 180 locations across the country.
CancerIQ is backed by Merck Global Health Innovation Fund, Amgen Ventures, McKesson Ventures, OSF Ventures, HealthX Ventures, Impact Engine, Lightbank, Rock Health, and others. The company raised $14M in Series B round on Mar 03, 2022. This brings CancerIQ's total funding to $20M to date.